Helius Medical Technologies is a neurotechnology company. Co. develops, licenses or acquires non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. Co.'s primary product, known as the Portable Neuromodulation Stimulator (PoNS), is authorized for sale in Canada as a class II, non-implantable medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis, and balance deficit due to mild-to-moderate traumatic brain injury, and is to be used in conjunction with supervised therapeutic exercise (PoNS Treatment). It is an investigational medical device in the U.S., the European Union, and Australia. The HSDT stock yearly return is shown above.
The yearly return on the HSDT stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the HSDT annual return calculation with any dividends reinvested as applicable (on ex-dates).
|